Juliana Matthews, MD
Endocrinology, Diabetes & Metabolism · Nashville, TNNPI 1790172765
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $10,283 of the $14,871 with a category attached, or 69.1%. 26 manufacturers reported payments, led by Dexcom, Inc. at 33.8% of the total. Reporting peaked in 2024 at $6,001 and has fallen 87.8% since, to $734 in 2025.
Across 456 payments — averaging $32.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dexcom, Inc.$5K
- Lilly USA, LLC$2K
- Amgen$1K
- AstraZeneca$1K
- Mannkind Corporation$1K
- Novo Nordisk$827
- plus $3K from 20 others
What the payments were for
- Speaking & faculty fees$4,58831%
- Food & beverage$10,28369%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dexcom, Inc. | 45 | $5,030 |
| Lilly USA, LLC | 68 | $1,643 |
| Amgen | 62 | $1,414 |
| AstraZeneca(2 entities) | 56 | $1,297 |
| Mannkind Corporation | 90 | $1,198 |
| Novo Nordisk | 28 | $827 |
| Cequr Corporation | 4 | $589 |
| Insulet Corporation | 19 | $431 |
| Sanofi-aventis U.S. LLC | 19 | $364 |
| Boehringer Ingelheim | 8 | $362 |
| Tandem Diabetes Care, Inc. | 5 | $215 |
| Xeris Pharmaceuticals, Inc. | 10 | $214 |
| Abbott | 11 | $194 |
| Corcept Therapeutics | 1 | $182 |
| Zealand Pharma US, Inc. | 2 | $128 |
| Amneal Pharmaceuticals LLC | 7 | $128 |
| Esperion Therapeutics, Inc. | 1 | $122 |
| Medtronic | 2 | $110 |
| Novartis | 2 | $97 |
| AbbVie | 4 | $83 |
| IBSA Pharma Inc. | 4 | $80 |
| Sequel Med Tech, LLC | 2 | $54 |
| BETA Bionics, Inc. | 3 | $44 |
| Bayer | 1 | $28 |
| Amphastar Pharmaceuticals, Inc. | 1 | $20 |
| Merck | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DEXCOM G7 GSS (161)$4,359
- CeQur Simplicity$511
- EVENITY$233
- Ozempic$222
- AFREZZA$210
- Korlym$182
- t:slim X2 Insulin Pump with Control-IQ$132
- DEXCOM G6 TRANSMITTER$127
- JARDIANCE$123
- NEXLIZET$122
- NEXLETOL$122
- Wegovy$121
- FARXIGA$121
- Repatha$120
- ZEGALOGUE$117
- Prolia$116
- RYBELSUS$108
- MOUNJARO$103
How this compares
$14,871 in reported general payments places this provider in the 70th percentile of 130 endocrinology, diabetes & metabolism providers in Tennessee.
See all endocrinology, diabetes & metabolism providers in Tennessee →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 215 | $214,972 |
| MounjaroTirzepatide | 158 | $183,213 |
| JardianceEmpagliflozin | 186 | $169,426 |
| TrulicityDulaglutide | 67 | $89,354 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 81 | $72,998 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 57 | $57,358 |
| Tresiba Flextouch U-100Insulin Degludec | 98 | $50,546 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 89 | $49,974 |
| Tresiba Flextouch U-200Insulin Degludec | 44 | $44,779 |
| FarxigaDapagliflozin Propanediol | 44 | $43,584 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 35 | $28,519 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 30 | $26,149 |
| ProliaDenosumab | 14 | $22,965 |
| Novolog FlexpenInsulin Aspart | 101 | $19,900 |
| RybelsusSemaglutide | 11 | $15,949 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Lyumjev, Humalog | $1,643 | $286,200249 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $827 | $237,267251 claims |
| Boehringer IngelheimJardiance | $362 | $169,426186 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $364 | $57,35857 claims |
| AstraZenecaFarxiga | $1,297 | $43,58444 claims |
| AmgenProlia | $1,414 | $22,96514 claims |
| Cequr CorporationCequr Simplicity | $589 | $5,49813 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $128 | $3,069329 claims |
| AbbVieSynthroid | $83 | $2,09921 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 130 endocrinology, diabetes & metabolism providers in Tennessee.
Other endocrinology, diabetes & metabolism in Nashville
- Craig WierumNashville$1.3M
- Terri JerkinsNashville$567K
- Michael CarlsonNashville$381K
- Kathryn DahirNashville$225K
- Rodney SnowNashville$181K
- Annis MarneyNashville$26K
- Emily NeelyNashville$21K
- Amanda DanielNashville$20K
- Christopher BowmanNashville$14K
- Cheryl FasslerNashville$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.